Dublin, April 04, 2017 -- Research and Markets has announced the addition of the "Global Markets for Diabetes Therapeutics and Diagnostics" report to their offering.
The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
Key Topics Covered:
1: Introduction
- Study Goals And Objectives
- Reasons For Doing The Study
- Scope Of Report
- Market Analyses And Forecasts
- Methodology
- Intended Audience
- Information Sources
2: Summary
- The Diabetes Market
- Leading Companies
3: Overview
- Diabetes Basics
- Current Treatment Of Diabetes
- The Diabetes Industry
4: Products And Suppliers
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Drugs
- Diagnosis And Monitoring
- Blood Glucose Monitoring Devices And Suppliers
- Other Testing Approaches
- Software Aids To Diabetes Monitoring
5: New Developments In Diabetes
- New Insulin Formulations And Combinations
- Improved Oral Antidiabetic Drugs
- New Developments In Glucose Testing
- Radical Approaches
6: The Global Diabetes Market
- Market Components
- Market Analysis By Product Category
- Trends
- Regional Segmentation
- National Markets
- National Markets In Detail
7: Company Profiles
- Leading Companies
- Other Companies
8: Appendix I About Diabetes
- Blood Sugar Regulation
- Insulin
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Obesity-Related Type 2 Diabetes In Children
- Mature-Onset Diabetes Of The Young (Mody)
- Other Diabetic States
9: Appendix
Companies Mentioned
- 77 Elektronika Kft.
- A. Menarini Diagnostics S.R.L.
- Abbott Laboratories
- Agamatrix Inc.
- Animas Corp.
- Ascensia
- Becton Dickinson
- Debiotech S.A.
- Eli Lilly And Co.
- Glaxo Smithkline
- Inlight Solutions Inc.
- Johnson & Johnson
- Lifescan Inc.
- Medtronic
- Merck & Co.
- Merck KGAA
- Nipro Corp.
- Novartis Pharma Ag
- Novo Nordisk A/S
- Owen Mumford Ltd.
- Palco Labs Inc.
- Roche
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
- Terumo Corp.
For more information about this report visit http://www.researchandmarkets.com/research/9sd6n2/global_markets
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diagnostics, Endocrine and Metabolic Disorders Drugs


Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



